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Background: Glial Growth Factor 2 (GGF2) is a neuregulin peptide critical for myocardial function. GGF2 improves left ventricular function (LVF) 
in animal models of cardiac injury. We report echocardiographic findings in a first-in-man, double-blind, placebo controlled, escalating single dose 
study of tolerability of GGF2 in patients with systolic HF.
methods: Patients with LV ejection fraction (EF) <40% and symptomatic HF (NYHA Class II-III) received a single IV dose of GGF2 (0.007[[Unable to 
Display Character: &#8211;]]1.5 mg/kg) or placebo (4:2) in 7 cohorts. Echocardiography was performed at baseline, days 8, 14, 28 and 90.
results: 40 patients (mean age 57 years, 82% male) were enrolled. EF at screening in the placebo and treatment groups was 29±3 and 27±1%, 
respectively. The change in EF (mean±SD) at D8, D14, and D28 was [[Unable to Display Character: &#8211;]]0.8±6.5, -1.1±7.8 and -0.3±8.5% for 
the placebo group compared to 2.3±8, 11.6±10 and 12±5.1% for the cohort receiving the maximally tolerated dose (0.75 mg/kg). Figure 1.
conclusions: Single dose GGF2 in patients with symptomatic HF showed a trend towards improving LVF over 28 days compared to 
placebo. Further studies will determine safety and possible therapeutic effect of repeat dosing of GGF2 on LVF and other cardiac outcomes.
 
